Pricing Log in Create free account

Arcutis Biotherapeutics, Inc. (ARQT) vs Telix Pharmaceuticals Limited (TLX)

Arcutis Biotherapeutics, Inc. and Telix Pharmaceuticals Limited are both Biotechnology companies. Arcutis Biotherapeutics, Inc. and Telix Pharmaceuticals Limited are of similar size ($3.7B and $3.6B). Across the 9 metrics below, Arcutis Biotherapeutics, Inc. leads on 8 and Telix Pharmaceuticals Limited on 1.

Valuation

Metric ARQT TLX Biotechnology median
P/E 131.00 — 8.50
P/S 8.11 — 9.71
P/B 17.05 n/m 2.13
Price to free cash flow 156.26 n/m 20.82
EV/EBITDA 102.13 n/m 0.64
EV/Sales 7.83 n/m 9.21
Earnings yield 0.76% — (33.15%)
Free cash flow yield 0.64% 0.00% (25.50%)

Profitability

Metric ARQT TLX Biotechnology median
Gross margin 91.14% — 65.16%
Operating margin 7.38% — 0.00%
Net margin 6.15% — 0.00%
Free cash flow margin 8.42% 0.00% 0.00%
Return on equity 15.86% 0.00% (56.36%)
Return on assets 6.78% 0.00% (48.04%)
Return on invested capital 23.62% 0.00% 0.00%

Growth

Metric ARQT TLX Biotechnology median
Revenue growth (TTM) 76.11% — 6.02%
EPS growth (last fiscal year) 88.79% (120.00%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ARQT TLX Biotechnology median
Debt to equity 0.49 1.18 0.00
Current ratio 2.92 2.01 4.72
Net debt to EBITDA 11.64 6.25 0.96

Dividend

Metric ARQT TLX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ARQT TLX Biotechnology median
Market cap 3.66b 3.60b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack